The Preferred Premedication Order to Prevent Infusion Reactions in Patients with Breast Cancer Receiving Pertuzumab Plus Trastuzumab and Docetaxel
Shigeru Nakagaki, Ryoichi Matsunuma, Kei Yamaguchi, Ryosuke Hayami & Michiko Tsuneizumi · Journal of Advances in Medicine and Medical Research · 2021
Aims:Pertuzumab plus trastuzumab and docetaxel is a standard regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the metastatic, adjuvant, and neoadjuvant settings. Infusion reaction represents one of the common side effects of anti-HER2 agents....
Open access
Research Article
10.9734/jammr/2021/v33i2231156